June 9, 2017 10:53 AM EDT

8 stars: A look back at ASCO spotlights the top cancer drugs to watch, and 1 to forget

I’ve been making the trek to ASCO for some years now, and I don’t recall any other week that rivals what I’ve just seen. There …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE LOG IN

TRENDING NOW

Trump asks 'very tough hombre' Dr. Oz to lead MFN talks

US warns drugmakers against misrepresenting cost of imported products

About 5% of CBER and CDER left after FDA staff cuts, analysis finds

Endpoints 100 biotech survey: Welcome to the summer of biotech’s discontent

Big leases, bigger regrets: Biotech slump turns swanky offices from asset into liability

sponsored

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?